logo
#

Latest news with #cancertreatment

Compass Therapeutics (CMPX) Gains Analyst Confidence with Promising Cancer Pipeline
Compass Therapeutics (CMPX) Gains Analyst Confidence with Promising Cancer Pipeline

Yahoo

time9 hours ago

  • Business
  • Yahoo

Compass Therapeutics (CMPX) Gains Analyst Confidence with Promising Cancer Pipeline

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the top high-return penny stocks to buy now. On July 14, Stifel reiterated its Buy rating and $11.00 price target for CMPX. The firm views the extended timeline for topline data from the Phase 2/3 COMPANION-002 trial—now expected in Q4 2025—as a positive, given the 19-month follow-up in a cancer type with typically short survival rates. A research team in lab coats testing a new ImmunoPhage platform in a modern biotechnology lab. Beyond COMPANION-002, Stifel highlighted two upcoming 2025 catalysts: Phase 1 results for CTX-8371, a PD-1xPD-L1 bispecific antibody, and preclinical data on CTX-10726 targeting PD-1 and VEGF-A. Interest is also growing around CTX-837's unique multi-modal mechanism, reinforcing Compass's innovation in immuno-oncology. Compass Therapeutics, Inc. (NASDAQ:CMPX) is a clinical-stage biotech company developing antibody-based cancer treatments in the U.S. Its lead candidates include bispecific antibodies like tovecimig (targeting DLL4 and VEGF-A), CTX-471 (stimulating CD137 for immune activation), and CTX-8371 (blocking PD-1/PD-L1). The company also advances CTX-10726 and VEGF-focused bispecifics aimed at enhancing anti-tumor immunity and inhibiting angiogenesis. While we acknowledge the potential of CMPX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Chemical Stocks to Buy According to Billionaires and 7 Most Undervalued Pot Stocks To Buy According To Analysts. Disclosure: None. This article is originally published at Insider Monkey.

H.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price Target
H.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price Target

Yahoo

time3 days ago

  • Business
  • Yahoo

H.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price Target

Vor Biopharma Inc. (NASDAQ:VOR) is one of the . In a report released on June 30, Swayampakula Ramakanth from H.C. Wainwright upgraded Vor Biopharma Inc. (NASDAQ:VOR) to a Buy with a price target of $3.00. The analyst based the optimistic outlook on the company's growth potential and strategic advancements. A scientist in a lab coat looking through a microscope at a petri dish of hematopoietic stem cells. Vor Biopharma Inc. (NASDAQ:VOR) recently announced an exclusive license agreement with RemeGen Co. for the development and commercialization of telitacicept in regions outside of Greater China. Telitacicept is a promising recombinant fusion protein and has already exhibited clinical success, attaining marketing approvals in China for a number of conditions, including generalized myasthenia gravis, systemic lupus nephritis, and rheumatoid arthritis. The analyst further reasoned that the financial structure of the agreement lends Vor Biopharma Inc. (NASDAQ:VOR) financial strength because it includes upfront payments and potential milestone payments. Vor Biopharma Inc. (NASDAQ:VOR) is a clinical-stage cell therapy company that develops cell therapies for the treatment of cancer. It combines therapies with a novel patient engineering approach to provide a single company solution for hematological malignancies. While we acknowledge the potential of VOR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

New test could revolutionise aftercare for thousands of breast cancer patients
New test could revolutionise aftercare for thousands of breast cancer patients

Yahoo

time4 days ago

  • Health
  • Yahoo

New test could revolutionise aftercare for thousands of breast cancer patients

Scientists have developed a new test for certain breast cancer patients which can predict whether or not their cancer is likely to return just two weeks after they start treatment. Experts said thousands of breast cancer patients could be spared unnecessary treatment as a result. The new test has been devised to detect the likelihood of cancer reoccurring in patients with a type of breast cancer known as oestrogen receptor positive, human epidermal growth factor receptor 2 positive – which accounts for around 200,000 cases of cancer each year around the globe. Writing in the journal eBioMedicine, experts said the test means that some patients will be able to 'de-escalate' their treatment while it could also help identify those who need 'more intensive therapeutic strategies'. The test, which was developed by scientists at The Institute for Cancer Research, London, correctly identifies the 6% of patients at highest risk of relapse. Researchers analysed tumour samples from 213 patients. They found that two weeks of hormone therapy changes the characteristics of some tumours, causing them to shift their subtype. The patients with the highest risk of cancer returning had a type of tumour called Luminal B that did not change after this short-term hormone therapy. Experts said these patients will require more intensive treatment. This is your breast check reminder! Learn the signs and symptoms of breast — Breast Cancer Now (@BreastCancerNow) May 6, 2025 They said the findings highlight the benefit of two weeks of hormone therapy before surgery to help guide doctors' decision making. Corresponding author of the study, Dr Maggie Cheang, from The Institute of Cancer Research, London, said: 'To deliver truly personalised care, we need to refine how we classify breast cancer, so that each patient receives the treatment most likely to benefit them. 'While current classification relies on hormone receptor and HER2 status, we know that patients within these groups can respond very differently to the same therapy. 'Our earlier research identified distinct molecular subtypes within HER2-positive, oestrogen receptor-positive breast cancer. In this new study, we've shown that these subtypes can shift after just two weeks of hormone therapy. 'This insight helps us identify which patients are likely to respond well and which may show early signs of treatment resistance, offering the opportunity to tailor treatment strategies sooner. 'Ultimately, our findings move us closer to more precise, patient-centred care for this overlooked breast cancer subtype.' Professor Kristian Helin, chief executive of The Institute of Cancer Research, London, added: 'By decoding the underlying biology of tumours, we can tailor treatments to individual patients.' Dr Simon Vincent, chief scientific officer at Breast Cancer Now, which part-funded the study, said: 'These findings add to the growing evidence that genomic testing can play a powerful role in helping to predict the risk of a woman's breast cancer coming back, particularly in people with ER-positive, HER2-positive breast cancer. 'There's potential for women to benefit hugely from this research in the future, with it ensuring they avoid undergoing unnecessary treatment and leading to more personalised treatment plans, so that women receive the most effective therapy for their specific type of breast cancer.'

Breast cancer breakthrough as new test could revolutionise treatment
Breast cancer breakthrough as new test could revolutionise treatment

The Independent

time4 days ago

  • Health
  • The Independent

Breast cancer breakthrough as new test could revolutionise treatment

A new test for breast cancer patients has been developed which can predict whether or not their cancer is likely to return just two weeks after they start treatment. Experts said thousands of breast cancer patients could be spared unnecessary treatment as a result. The new test has been devised by scientists to detect the likelihood of cancer reoccurring in patients with a type of breast cancer known as oestrogen receptor positive, human epidermal growth factor receptor 2 positive – which accounts for around 200,000 cases of cancer each year around the globe. Writing in the journal eBioMedicine, experts said the test means that some patients will be able to 'de-escalate' their treatment while it could also help identify those who need 'more intensive therapeutic strategies'. The test, which was developed by scientists at The Institute for Cancer Research, London, correctly identifies the 6% of patients at highest risk of relapse. Researchers analysed tumour samples from 213 patients. They found that two weeks of hormone therapy changes the characteristics of some tumours, causing them to shift their subtype. The patients with the highest risk of cancer returning had a type of tumour called Luminal B that did not change after this short-term hormone therapy. Experts said these patients will require more intensive treatment. They said the findings highlight the benefit of two weeks of hormone therapy before surgery to help guide doctors' decision making. Corresponding author of the study, Dr Maggie Cheang, from The Institute of Cancer Research, London, said: 'To deliver truly personalised care, we need to refine how we classify breast cancer, so that each patient receives the treatment most likely to benefit them. 'While current classification relies on hormone receptor and HER2 status, we know that patients within these groups can respond very differently to the same therapy. 'Our earlier research identified distinct molecular subtypes within HER2-positive, oestrogen receptor-positive breast cancer. In this new study, we've shown that these subtypes can shift after just two weeks of hormone therapy. 'This insight helps us identify which patients are likely to respond well and which may show early signs of treatment resistance, offering the opportunity to tailor treatment strategies sooner. 'Ultimately, our findings move us closer to more precise, patient-centred care for this overlooked breast cancer subtype.' Professor Kristian Helin, chief executive of The Institute of Cancer Research, London, added: 'By decoding the underlying biology of tumours, we can tailor treatments to individual patients.' Dr Simon Vincent, chief scientific officer at Breast Cancer Now, which part-funded the study, said: 'These findings add to the growing evidence that genomic testing can play a powerful role in helping to predict the risk of a woman's breast cancer coming back, particularly in people with ER-positive, HER2-positive breast cancer. 'There's potential for women to benefit hugely from this research in the future, with it ensuring they avoid undergoing unnecessary treatment and leading to more personalised treatment plans, so that women receive the most effective therapy for their specific type of breast cancer.'

Will Increased Expenses Affect Bristol Myers' Performance?
Will Increased Expenses Affect Bristol Myers' Performance?

Globe and Mail

time6 days ago

  • Business
  • Globe and Mail

Will Increased Expenses Affect Bristol Myers' Performance?

Last month, Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and co-commercialization of the latter's investigational bispecific antibody BNT327 across numerous solid tumor types. While the collaboration strengthens BMY's pipeline, the company will incur increased operating expenses. BMY will make an upfront payment of $1.5 billion to BNTX and pay a total of $2 billion in non-contingent anniversary payments through 2028. These tax-deductible charges will be recorded as acquired IPR&D Expense when incurred. Of the total expenses related to the deal, approximately $1.5 billion has most likely been incurred in the second quarter. This, in turn, will adversely impact the bottom line. BMY is already facing top-line pressure as the legacy portfolio is under pressure due to continued generic impact on Revlimid, Pomalyst, Sprycel and Abraxane. The sales of the blood thinner drug Eliquis are also affected due to the Medicare Part D redesign in the United States. Competition in Dual Target Cancer Therapy Space Heats Up Developing bispecific antibodies that target two proteins, namely PD-1 and VEGF, has lately been one of the lucrative areas in cancer treatment, attracting pharma giants Merck MRK and Pfizer PFE. In November 2024, Merck received an exclusive global license to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. Merck's oncology portfolio boasts a blockbuster PD-L1 inhibitor, Keytruda, and it is looking to build a diversified oncology pipeline spanning differentiated mechanisms and multiple modalities. Last month, Pfizer inked a licensing agreement with 3SBio for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside China. The candidate is already being evaluated in China for non-small cell lung cancer, metastatic colorectal cancer and gynecological tumors. Pfizer will also make an equity investment of $100 million in 3SBio upon the deal's closure. BMY's Price Performance, Valuation and Estimates Shares of Bristol Myers have lost 15% year to date against the industry 's growth of 1.3%. Image Source: Zacks Investment Research From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, BMY's shares currently trade at 7.40x forward earnings, lower than its mean of 8.53x and the large-cap pharma industry's 14.79X. Image Source: Zacks Investment Research The bottom-line estimate for 2025 has moved down to $6.52 from $6.89 in the past 60 days and that for 2026 has declined 5 cents. BMY currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report This article originally published on Zacks Investment Research (

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store